Lilly's Jaypirca Combo Reduces Risk Of Progression By 45% In Phase 3 CLL Trial

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) announced positive results from the Phase 3 BRUIN CLL-322 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase...